Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved three new indications for once-weekly Sogroya (R) (somapacitan-beco) injection 5 mg, 10 mg, or 15 mg, a ...

The first and only approved achondroplasia therapy to provide continuous systemic exposure to CNP over the weekly dosing intervalCommercial ...

The FDA has approved three new pediatric indications for somapacitan-beco, a once-weekly, long-acting growth hormone injection, according to a press release issued by Novo Nordisk.Somapacitan-beco ...

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved three new indications for ...

Almost a quarter of Florida’s residents who should be screened for this cancer aren't up-to-date with widely accepted ...

The U.S. Food and Drug Administration on Friday approved Ascendis Pharma's once-weekly therapy for children with a rare genetic disorder that causes dwarfism, the company said.

Monthly injections of long-acting cabotegravir-rilpivirine are superior to standard oral antiretroviral therapy (ART) in ...

Almost a quarter of Florida’s residents who should be screened for this cancer aren't up-to-date with widely accepted ...

Eli Lilly, the drugmaker behind weight-loss treatments Mounjaro and Zepbound, has rapidly overtaken former market leader Novo ...

GoodRx reports that the FDA has approved oral semaglutide (Wegovy) for weight loss, offering an alternative to injections ...

Studies show that women who use a contraceptive injection known as Depo-Provera could increase their risk of benign brain tumours by as much as 500 per cent.

Behind the buzz around Mounjaro lies a larger conversation about who really needs it.